Form 4: Alnylam Pharmaceuticals CEO Sells Shares After Performance-Based Stock Unit Vesting

Alnylam Pharmaceuticals CEO, Yvonne Greenstreet, sold a portion of her shares following the vesting of a performance-based stock unit, triggered by a positive clinical trial result and FDA acceptance of a new drug application.

Summary

• Alnylam Pharmaceuticals CEO, Yvonne Greenstreet, received 10,658 shares of common stock on November 25, 2024, due to the vesting of a performance-based stock unit (PSU).
• The PSU vested because Alnylam publicly reported FDA acceptance of a new drug application for a therapeutic to treat ATTR amyloidosis with cardiomyopathy, following a positive Phase 3 clinical trial result.
• On November 26, 2024, Ms. Greenstreet sold a total of 5,199 shares to cover tax obligations related to the vesting of the PSU.
• The sales occurred in multiple transactions at weighted average prices ranging from $247.77 to $252.27 per share.
• After these transactions, Ms. Greenstreet directly owns 78,880 shares and indirectly owns 407 shares through a managed account.

Sentiment

Score: 6

Explanation: The document reflects a positive milestone (FDA acceptance) but also includes share sales by the CEO, which could be interpreted neutrally or slightly negatively. The sales are for tax purposes, which is normal.

Positives

• The vesting of the performance-based stock unit indicates the achievement of a significant milestone for Alnylam, specifically the FDA acceptance of a new drug application.
• The positive Phase 3 clinical trial results for the ATTR amyloidosis treatment are a positive development for the company.

Negatives

• The sale of 5,199 shares by the CEO, while for tax obligations, could be perceived negatively by some investors.

Risks

• The sale of shares by a high-ranking executive could potentially create short-term volatility in the stock price.
• The market's reaction to the share sales could be influenced by overall market sentiment and the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions and is common in the pharmaceutical industry, especially after significant milestones like FDA acceptance of a new drug application. It reflects the company's progress in developing treatments for ATTR amyloidosis.

Comparison to Industry Standards

• Executive stock sales following vesting events are common across the pharmaceutical industry, particularly after positive clinical trial results or regulatory approvals.
• Companies like Ionis Pharmaceuticals and Sarepta Therapeutics also have similar insider transaction filings after achieving milestones.
• The sale of shares to cover tax obligations is a standard practice and does not necessarily indicate a lack of confidence in the company's future.

Stakeholder Impact

• Shareholders may react to the CEO's share sales, potentially causing short-term price fluctuations.
• Employees may view the vesting of the PSU as a positive sign of the company's progress.
• The positive clinical trial results and FDA acceptance are positive for patients who may benefit from the new treatment.

Key Dates

Keywords

Alnylam Pharmaceuticals, Yvonne Greenstreet, stock sale, performance-based stock unit, FDA approval, ATTR amyloidosis, clinical trial, insider trading, executive compensation